Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share

Equities analysts forecast that Viking Therapeutics, Inc. (NASDAQ:VKTX) will post ($0.19) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.19). Viking Therapeutics reported earnings per share of ($0.18) during the same quarter last year, which would indicate a negative year over year growth rate of 5.6%. The company is scheduled to announce its next earnings report on Tuesday, March 20th.

According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.86) per share for the current fiscal year, with EPS estimates ranging from ($0.87) to ($0.85). For the next fiscal year, analysts forecast that the company will post earnings of ($0.68) per share, with EPS estimates ranging from ($0.72) to ($0.60). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03).

Several brokerages recently issued reports on VKTX. ValuEngine cut Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Maxim Group set a $8.00 price target on Viking Therapeutics and gave the company a “buy” rating in a research note on Tuesday, November 28th. Roth Capital began coverage on Viking Therapeutics in a research note on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a research note on Friday, November 10th.

Shares of Viking Therapeutics (NASDAQ:VKTX) traded up $0.38 during mid-day trading on Friday, hitting $4.08. The company had a trading volume of 3,035,271 shares, compared to its average volume of 1,250,440. Viking Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $4.15.

Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of Viking Therapeutics during the third quarter worth $108,000. Sphera Funds Management LTD. acquired a new position in shares of Viking Therapeutics during the third quarter worth $554,000. Sabby Management LLC acquired a new position in shares of Viking Therapeutics during the second quarter worth $525,000. Virtu KCG Holdings LLC acquired a new position in shares of Viking Therapeutics during the second quarter worth $124,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Viking Therapeutics by 62.9% during the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after buying an additional 102,600 shares in the last quarter. Institutional investors own 7.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/09/brokerages-expect-viking-therapeutics-inc-vktx-to-post-0-19-earnings-per-share.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply